We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+14.65%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$331M
AUM Growth
+$11.7M
Cap. Flow
-$13.4M
Cap. Flow %
-4.06%
Top 10 Hldgs %
42.42%
Holding
75
New
12
Increased
16
Reduced
23
Closed
21

Top Buys

1
NVO
Novo Nordisk
NVO
+$14.7M
2
BPMC
Blueprint Medicines
BPMC
+$9.93M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.99M
4
JANX icon
Janux Therapeutics
JANX
+$6.09M
5
DYN icon
Dyne Therapeutics
DYN
+$3.98M

Top Sells

1
BHVN icon
Biohaven
BHVN
+$19.1M
2
VRDN icon
Viridian Therapeutics
VRDN
+$8.38M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$8.04M
4
SLNO
Soleno Therapeutics
SLNO
+$7.18M
5
PCVX icon
Vaxcyte
PCVX
+$6.31M

Sector Composition

1 Healthcare 83.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATYR
51
aTyr Pharma
ATYR
$50M
$1.41M 0.43%
800,000
– –
LRMR icon
52
Larimar Therapeutics
LRMR
$384M
$1.31M 0.4%
+200,000
New +$1.61M
ENGN icon
53
enGene Therapeutics
ENGN
$122M
$1.06M 0.32%
160,898
-259,433
-62% -$1.93M
AMLX icon
54
Amylyx Pharmaceuticals
AMLX
$1.97B
$1.05M 0.32%
+325,000
New +$731K
ACAD icon
55
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-225,000
Closed -$3.66M
ALNY icon
56
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-22,500
Closed -$5.47M
ALNY icon
57
PUT
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-68,400
Closed -$16.6M
ANNX icon
58
CALL
Annexon
ANNX
$950M
– –
-214,500
Closed -$1.05M
ANTX icon
59
AN2 Therapeutics
ANTX
$169M
– –
-219,331
Closed -$472K
ARWR icon
60
Arrowhead Research
ARWR
$10.5B
– –
-35,000
Closed -$910K
BHVN icon
61
Biohaven
BHVN
$2.32B
– –
-490,000
Closed -$19.1M
CABA icon
62
Cabaletta Bio
CABA
$461M
– –
-370,899
Closed -$2.77M
CTMX icon
63
CytomX Therapeutics
CTMX
$788M
– –
-300,000
Closed -$366K
CYTK icon
64
Cytokinetics
CYTK
$10.9B
– –
-33,200
Closed -$1.8M
ELEV
65
DELISTED
Elevation Oncology
ELEV
– –
-600,000
Closed -$1.62M
KRYS icon
66
Krystal Biotech
KRYS
$10.5B
– –
-8,500
Closed -$1.56M
MGNX icon
67
MacroGenics
MGNX
$285M
– –
-150,000
Closed -$638K
NTLA icon
68
Intellia Therapeutics
NTLA
$1.59B
– –
-25,000
Closed -$560K
PMVP icon
69
PMV Pharmaceuticals
PMVP
$71.5M
– –
-375,000
Closed -$608K
PTCT icon
70
PTC Therapeutics
PTCT
$6.52B
– –
-19,000
Closed -$581K
RAPT
71
CALL
DELISTED
RAPT Therapeutics
RAPT
– –
-37,500
Closed -$915K
SGMT icon
72
Sagimet Biosciences
SGMT
$483M
– –
-225,000
Closed -$770K
WVE icon
73
Wave Life Sciences
WVE
$1.12B
– –
-200,000
Closed -$998K
ITCI
74
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-10,000
Closed -$685K
RVNC
75
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-225,000
Closed -$578K
1 2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Ghost Tree Capital held 75 positions worth $331M, up 3.7% from $319M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ghost Tree Capital withdrew a net $13.4M in Q3 2024, closing 21 positions and reducing 23 holdings. Its most notable exit was Biohaven, an estimated $19.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 90% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Novo Nordisk worth $13.1M.

  • Ghost Tree Capital's largest Q3 2024 buy was Novo Nordisk: 110,000 shares worth $13.1M.
  • Ghost Tree Capital added most to Blueprint Medicines in Q3 2024, an estimated $9.93M increase.
  • Ghost Tree Capital's biggest Q3 2024 reduction was Viridian Therapeutics, cutting an estimated $8.38M.
  • Ghost Tree Capital fully exited Biohaven in Q3 2024, selling an estimated $19.1M.
  • Ghost Tree Capital's ten largest holdings make up 42% of its $331M portfolio in Q3 2024.
  • Ghost Tree Capital opened 12 new positions and closed 21 in Q3 2024.
  • Ghost Tree Capital's portfolio value rose 3.7% quarter-over-quarter to $331M.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.